Investigational drug · Phase 3
EXV-801
Also called: deramciclane
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Agitation Associated With Alzheimer's Disease Dementia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EXV-801"
First trial start
2026
Feb 2, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EXV-801", any sponsor or status.
Conditions studied
As listed on its trial records.
- Agitation Associated With Alzheimer's Disease Dementia
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "EXV-801" as an intervention, largest first.
- Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease DementiaPivotal-lookingRecruiting
Exciva GmbHIndustry
NCT07284472 · 300 participants (planned) · Start Feb 2, 2026 · Primary completion Jan 2029
Drug: EXV-802; Placebo and 1 more · For: Agitation Associated With Alzheimer's Disease Dementia
Sites: Murrieta, California; Indianapolis, Indiana; Flowood, Mississippi · 49 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Selective binding interactions of deramciclane to the genetic variants of human alpha(1)-acid glycoprotein.
Fitos I, Visy J, Simonyi M, et al. · Biochim Biophys Acta 2010
- Deramciclane improves object recognition in rats: potential role of NMDA receptors.
Kertész S, Kapus G, Gacsályi I, et al. · Pharmacol Biochem Behav 2010
- Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.
Kääriäinen TM, Lehtonen M, Forsberg MM, et al. · Basic Clin Pharmacol Toxicol 2008
- Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H, Raassina R, Penttinen J, et al. · Eur Neuropsychopharmacol 2005
- Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human.
Monostory K, Kohalmy K, Ludányi K, et al. · Drug Metab Dispos 2005
- Role of CYP2E1 in deramciclane metabolism.
Monostory K, Köhalmy K, Hazai E, et al. · Drug Metab Dispos 2005
Also in development for Agitation Associated With Alzheimer's Disease Dementia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.